Case Summary (G.R. No. 197802)
Key Dates and Registrations
- Petitioners’ BFAD application for CPR: October 2, 2001 (name ZYNAPS indicated); CPR issued April 15, 2003.
- Respondent’s trademark registration (ZYNAPSE) with the Intellectual Property Office: Certificate issued September 24, 2007 (10-year term from that date).
- Respondent’s cease-and-desist letter to petitioners: October 30, 2007.
- RTC interlocutory rulings: denial of TRO (December 21, 2007) and denial of writ of preliminary injunction (March 12, 2008).
- Court of Appeals (CA) interlocutory rulings: denial of petition for certiorari re preliminary injunction (June 17, 2008 and denial of reconsideration July 31, 2008); later CA Decision granting certiorari and issuing permanent injunction (April 18, 2011) and denial of reconsideration (July 21, 2011).
- RTC final decision on the merits: December 2, 2011 (awarding damages, exemplary damages, attorney’s fees; ordering injunction and destruction/disposal of infringing items).
- Appeal from the RTC merits decision was pending before the Supreme Court (docketed as G.R. No. 211850).
Facts Material to the Dispute
Natrapharm manufactures and markets citicoline under the registered trademark ZYNAPSE and had obtained corresponding regulatory permits. Petitioners imported and sold carbamazepine under the brand name ZYNAPS, with a BFAD CPR issued in 2003 and an application showing use as early as 2001. The two trade names are pronounced identically and are nearly identical in spelling. Respondent alleged likelihood of confusion and medicine switching—with particular concern that carbamazepine has a known severe side-effect (Stevens‑Johnson Syndrome)—and demanded cessation of the use of ZYNAPS. Petitioners asserted prior good-faith use protected under Section 159 of the Intellectual Property Code (limitation of registrant’s rights against prior users).
Procedural Posture and Relief Sought
Respondent filed an infringement complaint and sought interlocutory relief (TRO and writ of preliminary injunction) from the Regional Trial Court (RTC). The RTC denied both interlocutory remedies, finding petitioners’ prior use persuasive under Section 159. Respondent filed a petition for certiorari with the CA to challenge the RTC’s denial of preliminary injunction. The CA initially denied relief but later (in a decision on certiorari) granted the petition and issued a permanent injunction prohibiting petitioners’ use of ZYNAPS and similar marks. Meanwhile, the RTC proceeded to trial on the merits and, in its December 2, 2011 decision, awarded damages to respondent, permanently enjoined defendants from using ZYNAPS or confusingly similar marks, and ordered disposal/destruction of infringing materials. Petitioners sought review by the Supreme Court under Rule 45, contesting the CA’s issuance of a permanent injunction in the certiorari proceeding.
Issues Raised on Review
The petition before the Supreme Court presented two central questions:
- Whether the CA’s issuance of a permanent injunction in a certiorari proceeding challenging the denial of an application for a preliminary injunction was proper (i.e., whether the CA erred in granting permanent injunctive relief when it was acting on a petition for certiorari against an interlocutory RTC order).
- Whether the matters raised in the petition had been rendered moot and academic by the RTC’s subsequent final decision on the merits (which itself included a permanent injunction and other relief).
Supreme Court’s Analysis on Mootness and Nature of Injunctive Relief
The Court emphasized the fundamental distinction between preliminary and permanent injunctions under Rule 58 of the Rules of Court. A preliminary injunction is interlocutory, granted on the basis of initial or incomplete evidence at any stage prior to final judgment; a permanent injunction is part of and flows from the final judgment after a hearing on the merits. Because a preliminary injunction is ancillary to the main action, it ordinarily cannot survive and is superseded by the final decision on the merits. The Court cited precedent and authorities establishing that interlocutory orders lose their operative force once the main case is adjudicated and a final judgment (with any attendant permanent injunction) is rendered.
Application of Legal Principles to the Present Case
Given that the RTC had rendered a final decision on the merits (December 2, 2011) that included a permanent injunction, the Court held that the issues presented in the Rule 45 petition — which primarily challenged the CA’s action in relation to a denial of preliminary relief — had become moot and academic. The presence of a subsequent final adjudication with an equivalent permanent
...continue readingCase Syllabus (G.R. No. 197802)
Procedural Posture
- Petition for review under Rule 45 of the 1997 Rules of Civil Procedure, as amended, raising issues from the Court of Appeals (CA) Decision dated April 18, 2011 and CA Resolution dated July 21, 2011 in CA-G.R. SP No. 103333.
- CA granted a permanent injunction in favor of respondent Natrapharm, Inc. and against petitioners Zuneca Pharmaceutical, Akram Arain and/or Venus Arain, M.D. dba Zuneca Pharmaceutical.
- The Regional Trial Court (RTC), Branch 93, Quezon City, earlier denied applications for a temporary restraining order (TRO) and a writ of preliminary injunction in orders dated December 21, 2007 and March 12, 2008, respectively.
- CA initially denied respondent’s petition for certiorari seeking a TRO/ preliminary injunction (Resolution dated June 17, 2008) and denied reconsideration (Resolution dated July 31, 2008), but later, in an April 18, 2011 Decision, reversed the RTC and permanently enjoined petitioners from using “ZYNAPS.”
- Petitioners’ motion for reconsideration before the CA was denied on July 21, 2011; petition for review was filed in the Supreme Court.
- The RTC rendered a Decision on the merits on December 2, 2011 in the main action (Injunction, Trademark Infringement, Damages and Destruction), awarding damages and permanently enjoining defendants from using ZYNAPS or confusingly similar marks and ordering disposal/destruction of infringing materials.
- The Supreme Court ultimately denied the Rule 45 petition as moot and academic, because the RTC’s December 2, 2011 Decision on the merits rendered the issues raised in the petition academic.
Parties and Subject Matter
- Respondent: Natrapharm, Inc., an all-Filipino pharmaceutical company, manufacturer and seller of a medicine bearing the generic name “CITICOLINE,” marketed under the registered trademark “ZYNAPSE.”
- Petitioners: Zuneca Pharmaceutical, Akram Arain and/or Venus Arain, M.D., doing business as Zuneca Pharmaceutical; sellers of an imported medicine bearing the generic name “CARBAMAZEPINE,” marketed under the brand name “ZYNAPS.”
- Core subject: Alleged trademark infringement and request for injunctive relief over the use of the marks “ZYNAPSE” (registered) and “ZYNAPS” (unregistered), and related claims for damages and destruction/disposal of infringing materials.
Registrations, Permits, and Dates
- Natrapharm’s trademark “ZYNAPSE”:
- Registered with the Intellectual Property Office (IPO) on September 24, 2007 under Certificate of Trademark Registration No. 4-2007-005596.
- Registration term: protection for 10 years from September 24, 2007 (as stated in the source).
- Natrapharm obtained from the Bureau of Food and Drugs (BFAD) the necessary permits and licenses to register, list and sell its “ZYNAPSE” medicine in its various forms and dosages.
- Petitioners’ product “ZYNAPS”:
- Alleged use since 2003 or even as early as 2001.
- Issuance by BFAD of a Certificate of Product Registration (CPR) on April 15, 2003, permitting sale of CARBAMAZEPINE under the brand name “ZYNAPS.”
- Petitioners submitted their BFAD CPR application on October 2, 2001, with “ZYNAPS” indicated.
Factual Background and Chronology
- Petitioners have been selling CARBAMAZEPINE under the brand name “ZYNAPS” (imported from Lahore, Pakistan) allegedly since 2003 or 2001.
- Respondent markets CITICOLINE under the registered mark “ZYNAPSE.” “ZYNAPS” is pronounced exactly like “ZYNAPSE.”
- Respondent alleged both products were sold in numerous drugstores where the coexistence of the two marks could lead to confusion and medicine switching.
- Respondent claimed CARBAMAZEPINE has a documented serious and disfiguring side-effect called “Stevens-Johnson Syndrome,” and argued that medicine switching between “ZYNAPSE” and “ZYNAPS” could place patients at risk.
- On October 30, 2007, respondent sent petitioners a cease-and-desist demand letter asserting Natrapharm’s exclusive trademark rights and warning of confusing similarity and danger of medicine switching.
- Petitioners refused the demand, relying on their prior use and BFAD CPR dated April 15, 2003.
- On November 29, 2007, respondent filed a complaint for trademark infringement under R.A. No. 8293 (Intellectual Property Code), with prayer for a TRO and/or writ of preliminary injunction.
- RTC denied TRO (Order dated December 21, 2007) and denied writ of preliminary injunction (Order dated March 12, 2008), holding petitioner’s prior actual use in 2003 defeated the registrant’s claim, invoking Section 159 of the IPC.
- CA initially denied certiorari relief (Resolution dated June 17, 2008) and denied reconsideration (July 31, 2008).
- CA later, in its April 18, 2011 Decision, granted the petition for certiorari, reversed the RTC Omnibus Order dated March 12, 2008, and permanently enjoined petitioners from using “ZYNAPS” or any confusingly similar name.
- Petitioners’ motion for reconsideration before the CA was denied in a July 21, 2011 Resolution.
- On December 2, 2011, the RTC rendered a Decision on the merits finding petitioners liable, awarding damages and ancillary relief, enjoining further use of “ZYNAPS” (or confusing variations), and ordering disposal or destruction outside channels of commerce of infringing items without compensation.
- Respondent moved to dismiss the Supreme Court petition as moot and academic in view of the RTC’s December 2, 2011 Decision on the merits; petitioners opposed, arguing the RTC decision had not attained finality.
Issues Presented to the Supreme Court
- Whether the decision on the merits rendered the issues in this case moot and academic.
- Whether the Court of Appeals may order a permanent injunction in deciding a petition for certiorari directed against the denial by the RTC of an application for a preliminary injunction.
Parties’ Contentions (as presented in the source)
- Respondent (Natrapharm, Inc.):
- Relied on IPO registration of “ZYNAPSE” and statutory exclusivity under Section 122 of R.A. No. 8293.
- Invoked Sections 138 and 147.1 of the IPC to assert that certificate of registration is prima facie evidence of ownership and exclusive right to use the mark and to prevent third parties from using confusingly similar marks.
- Cited precedent Conrad and Company, Inc. v. Court of Appeals (316 Phil. 850 (1995)) to assert entitlement to injunctive relief upon invasion of a registered mark.
- Emphasized danger of medicine switching due to the serious side-effect of CARBAMAZEPINE.
- Petitioners (Zuneca Pharmaceutical et al.):
- Asserted prior use in good faith of “ZYNAPS,” supported by BFAD CPR application dated October 2, 2001 and CPR issuance April 15, 2003.
- Invoked Section 159 of the IPC limiting the effect of registration against prior users; claimed right to continue use based on prior use.
Relevant Statutory and Doctrinal Provisions Cited in the Source
- R.A. N